Company
Immunocore
Immunocore has 11 drugs tracked on RxWires: 2 in Phase 3, 3 in Phase 2, 3 in Phase 1/2, 3 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Tebentafusp | Phase 3 | Uveal Melanoma |
| Brenetafusp | Phase 3 | Advanced Melanoma |
| Dexamethasone | Phase 2 | Uveal Melanoma, Metastatic |
| Tebentafusp-Tebn | Phase 2 | Locally Advanced Unresectable Uveal Melanoma |
| IMCgp100 | Phase 2 | Malignant Melanoma |
| IMCnyeso | Phase 1/2 | Select Advanced Solid Tumors |
| IMC-C103C | Phase 1/2 | Select Advanced Solid Tumors |
| IMC-R117C | Phase 1/2 | Cancer |
| IMC-S118AI | Phase 1 | Type 1 Diabetes |
| IMC-I109V Single Ascending Dose | Phase 1 | Hepatitis B, Chronic |
| IMC-P115C | Phase 1 | PRAME Positive |
Latest
- immunocore filed 8-K
- immunocore filed 8-K
- immunocore filed 8-K
- immunocore filed 8-K
- immunocore filed 8-K
Follow Immunocore on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.